PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35?
PURPOSE: To compare PCA3 score cut-off of 35 vs 20 in PCa diagnosis in patients undergoing repeated saturation prostate biopsy (SPBx). MATERIALS AND METHODS: From January 2010 to May 2011, 118 patients (median 62.5 years) with primary negative extended biopsy underwent a transperineal SPBx (median 30 cores) for persistent suspicion of PCa. The indications for repeated biopsy were: persistently high or increasing PSA values; PSA > 10 ng/mL, PSA values between 4.1-10 or 2.6-4 ng/mL with free/total PSA ≤ 25% and ≤ 20%, respectively; moreover, before performing SPBx urinary PCA3 score was evaluated. RESULTS: All patients had negative DRE and median PSA was 8.5 ng/mL (range: 3.7-24 ng/mL). A T1c PCa was found in 32 patients (27.1%): PCA3 score was 59 (median; range: 7-201) in the presence of PCa and 35 (median; range: 3-253) in the absence of cancer (p < 0.05). In the presence of ASAP and HGPIN median PCA3 score was 109 (range: 42-253) and 40 (range: 30-140), respectively. Diagnostic accuracy, sensitivity, specificity, PPV and NPV of PCA3 score cut-off of 20 vs 35 in PCa diagnosis were 44.9 vs 50%, 90.6 vs 71.9%, 27.9 vs 41.8%, 31.9 vs 31.5% and 88.9 vs 80%, respectively. ROC analysis demonstrated an AUC for PCA3 ≥ 20 vs ≥ 35 of 0.678 and 0.634, respectively. CONCLUSIONS: Our data suggest that PCA3 is more useful as an exclusion tool; moreover, setting a PCA3 cut-off at 20 vs 35, would have avoided 22.9 vs 38.1% of biopsies while missing 9.4% and 28% diagnosis of PCa.
Main Authors: | , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Sociedade Brasileira de Urologia
2012
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382012000400008 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S1677-55382012000400008 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S1677-553820120004000082012-09-20PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35?Pepe,PietroFraggetta,FilippoGalia,AntonioSkonieczny,GiorgioAragona,Francesco PCA3 prostate cancer diagnosis biopsy PURPOSE: To compare PCA3 score cut-off of 35 vs 20 in PCa diagnosis in patients undergoing repeated saturation prostate biopsy (SPBx). MATERIALS AND METHODS: From January 2010 to May 2011, 118 patients (median 62.5 years) with primary negative extended biopsy underwent a transperineal SPBx (median 30 cores) for persistent suspicion of PCa. The indications for repeated biopsy were: persistently high or increasing PSA values; PSA > 10 ng/mL, PSA values between 4.1-10 or 2.6-4 ng/mL with free/total PSA ≤ 25% and ≤ 20%, respectively; moreover, before performing SPBx urinary PCA3 score was evaluated. RESULTS: All patients had negative DRE and median PSA was 8.5 ng/mL (range: 3.7-24 ng/mL). A T1c PCa was found in 32 patients (27.1%): PCA3 score was 59 (median; range: 7-201) in the presence of PCa and 35 (median; range: 3-253) in the absence of cancer (p < 0.05). In the presence of ASAP and HGPIN median PCA3 score was 109 (range: 42-253) and 40 (range: 30-140), respectively. Diagnostic accuracy, sensitivity, specificity, PPV and NPV of PCA3 score cut-off of 20 vs 35 in PCa diagnosis were 44.9 vs 50%, 90.6 vs 71.9%, 27.9 vs 41.8%, 31.9 vs 31.5% and 88.9 vs 80%, respectively. ROC analysis demonstrated an AUC for PCA3 ≥ 20 vs ≥ 35 of 0.678 and 0.634, respectively. CONCLUSIONS: Our data suggest that PCA3 is more useful as an exclusion tool; moreover, setting a PCA3 cut-off at 20 vs 35, would have avoided 22.9 vs 38.1% of biopsies while missing 9.4% and 28% diagnosis of PCa.info:eu-repo/semantics/openAccessSociedade Brasileira de UrologiaInternational braz j urol v.38 n.4 20122012-08-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382012000400008en10.1590/S1677-55382012000400008 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Pepe,Pietro Fraggetta,Filippo Galia,Antonio Skonieczny,Giorgio Aragona,Francesco |
spellingShingle |
Pepe,Pietro Fraggetta,Filippo Galia,Antonio Skonieczny,Giorgio Aragona,Francesco PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35? |
author_facet |
Pepe,Pietro Fraggetta,Filippo Galia,Antonio Skonieczny,Giorgio Aragona,Francesco |
author_sort |
Pepe,Pietro |
title |
PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35? |
title_short |
PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35? |
title_full |
PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35? |
title_fullStr |
PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35? |
title_full_unstemmed |
PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35? |
title_sort |
pca3 score and prostate cancer diagnosis at repeated saturation biopsy. which cut-off: 20 or 35? |
description |
PURPOSE: To compare PCA3 score cut-off of 35 vs 20 in PCa diagnosis in patients undergoing repeated saturation prostate biopsy (SPBx). MATERIALS AND METHODS: From January 2010 to May 2011, 118 patients (median 62.5 years) with primary negative extended biopsy underwent a transperineal SPBx (median 30 cores) for persistent suspicion of PCa. The indications for repeated biopsy were: persistently high or increasing PSA values; PSA > 10 ng/mL, PSA values between 4.1-10 or 2.6-4 ng/mL with free/total PSA ≤ 25% and ≤ 20%, respectively; moreover, before performing SPBx urinary PCA3 score was evaluated. RESULTS: All patients had negative DRE and median PSA was 8.5 ng/mL (range: 3.7-24 ng/mL). A T1c PCa was found in 32 patients (27.1%): PCA3 score was 59 (median; range: 7-201) in the presence of PCa and 35 (median; range: 3-253) in the absence of cancer (p < 0.05). In the presence of ASAP and HGPIN median PCA3 score was 109 (range: 42-253) and 40 (range: 30-140), respectively. Diagnostic accuracy, sensitivity, specificity, PPV and NPV of PCA3 score cut-off of 20 vs 35 in PCa diagnosis were 44.9 vs 50%, 90.6 vs 71.9%, 27.9 vs 41.8%, 31.9 vs 31.5% and 88.9 vs 80%, respectively. ROC analysis demonstrated an AUC for PCA3 ≥ 20 vs ≥ 35 of 0.678 and 0.634, respectively. CONCLUSIONS: Our data suggest that PCA3 is more useful as an exclusion tool; moreover, setting a PCA3 cut-off at 20 vs 35, would have avoided 22.9 vs 38.1% of biopsies while missing 9.4% and 28% diagnosis of PCa. |
publisher |
Sociedade Brasileira de Urologia |
publishDate |
2012 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382012000400008 |
work_keys_str_mv |
AT pepepietro pca3scoreandprostatecancerdiagnosisatrepeatedsaturationbiopsywhichcutoff20or35 AT fraggettafilippo pca3scoreandprostatecancerdiagnosisatrepeatedsaturationbiopsywhichcutoff20or35 AT galiaantonio pca3scoreandprostatecancerdiagnosisatrepeatedsaturationbiopsywhichcutoff20or35 AT skoniecznygiorgio pca3scoreandprostatecancerdiagnosisatrepeatedsaturationbiopsywhichcutoff20or35 AT aragonafrancesco pca3scoreandprostatecancerdiagnosisatrepeatedsaturationbiopsywhichcutoff20or35 |
_version_ |
1756428120378834944 |